DEVIN BOURGEOIS: Open Payments
NPI 1669913943 · THIBODAUX, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,152 in 148 payments from 32 companies in 2025. Trend: 2023 $1,605 · 2024 $2,129 · 2025 $7,152
Consulting: $3,750Food & beverage: $3,006Travel & lodging: $331Education: $65
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $4,137 |
| ABBVIE INC. | 19 | $407 |
| PFIZER INC. | 13 | $255 |
| AstraZeneca Pharmaceuticals LP | 7 | $244 |
| Novo Nordisk Inc | 12 | $231 |
| Otsuka America Pharmaceutical, Inc. | 10 | $192 |
| Amgen Inc. | 13 | $173 |
| Medtronic, Inc. | 1 | $172 |
| GlaxoSmithKline, LLC. | 8 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $119 |
Products named: MOUNJARO, REXULTI, PROTEGE RX, ELIQUIS, UBRELVY, FARXIGA, OTEZLA, Ozempic.
Industry payments across LA — which companies pay providers there.
